Rev Esp Quimioter 2022; 35(3): 279-283

Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience

MARÍA OLMEDO, MARTA KESTLER, MARICELA VALERIO, BELÉN PADILLA, CARMEN RODRÍGUEZ GONZÁLEZ, ESTHER CHAMORRO, MARINA MACHADO, ANA ÁLVAREZ-URÍA, LUIS ALCALÁ, PATRICIA MUÑOZ, EMILIO BOUZA

Published: 14 March 2022

http://www.doi.org/10.37201/req/120.2021

Background. Following the approval of bezlotoxumab in 2017, studies evaluating its effectiveness in prevention of Clostridioides difficile infection under “real-life” conditions are scarce.
Material and methods. We conducted a retrospective study developed in a large tertiary care hospital describing the use and outcomes of patients with Clostridioides difficile infection (CDI) treated with bezlotoxumab.
Results. A total of 16 patients were include, all of whom had an episode of CDI with high probability of recurrence and 14 of them had some kind of immunosuppression. Bezlotoxumab was effective in the prevention of CDI recurrence in 11 of the 14 cases in which follow up was possible, without significant side effects.
Conclusions. Bezlotoxumab was well tolerated and the incidence of recurrent CDI in a high-risk population for recurrence was only 21.4%.

Rev Esp Quimioter 2022; 35(3): 279-283 [Full-text PDF]